Utility of Oncotype DX Risk Estimates in Clinically Intermediate Risk Hormone Receptor-Positive, HER2-Normal, Grade II, Lymph Node-Negative Breast Cancers.

The article discusses a study on clinical and pathological characteristics of breast cancer patients referred for Oncotype DX testing. The test was ordered when Oncotype DX result was considered useful for decision making for stratifying patients into either low or high-risk groups. The study confirms that Oncotype DX results often provide information risk assignments in patients considered at indeterminate risk.